Consultant for Translational R&D

  • Efficacious drugs in therapeutic areas with high unmet medical need
  • Safety margin resulting in convincing therapeutic window and allowing individual dosing
  • Precision drugs targeting the right patient population and reducing failure rate
  • Successful translational research strategy based on human drug target validation
  • Decisive data enabling go/no-go decisions
  • Risk mitigation strategy
  • Identifies key experiments mitigating the risk of clinical failure
  • Integrates clinical and non-clinical requirements to speed up drug development
  • Anticipates and considers regulatory needs for successful milestone coverage
  • Efficacious drugs in therapeutic areas with high unmet medical need
  • Safety margin resulting in convincing therapeutic window and allowing individual dosing
  • Precision drugs targeting the right patient population and reducing failure rate
  • Successful translational research strategy based on human drug target validation
  • Decisive data enabling go/no-go decisions
  • Risk mitigation strategy
  • Identifies key experiments mitigating the risk of clinical failure
  • Integrates clinical and non-clinical requirements to speed up drug development
  • Anticipates and considers regulatory needs for successful milestone coverage

Thomas Christoph, PhD

“I am fascinated by Translational Pharmacology, the interface between
non-clinical and clinical efficacy. I am convinced that human Target
Validation and continuous development of the 3R’s will increase the
Translational Value in Drug Development.”

Blog

EFIC 2025, Day 2/3, Friday April 25

25.04.2025|

Interesting new data on CRPS, neurotoxic peptides such as BoNT-A and on repeated treatment with high concentration capsaicin patch.

EFIC 2025, Day 1/3, Thursday April 24

24.04.2025|

From April 24 to 26, pain specialists and researchers convene in Lyon at the EFIC 2025. I continue with my personal selection of notable poster presentations regarding translational pain research.